drugset / Trial / NCT02184312
Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study to determine the pharmacokinetic properties of 200 mg (2 x 100 mg tablets once daily) and 300 mg (3 x 100 mg tablets once daily) Nevirapine extended release formulations and to estimate relative bioavailability of these formulations as compared to 200 mg VIRAMUNE® tablet as well as to 400 mg Nevirapine extended release tablet
Timeline
- Start
- 2008-04
- Primary completion
- 2008-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nevirapine | Small molecule | 200 mg | Oral |
| Subject | Nevirapine | Small molecule | 300 mg | Oral |
| Subject | Nevirapine | Small molecule | 400 mg | Oral |
Indications
No indication recorded.